Nutriband CEO Gareth Sheridan Publishes Letter to Shareholders, Outlines 2025 Achievements and 2026 Outlook
ByAinvest
Wednesday, Dec 31, 2025 7:01 am ET1min read
NTRB--
Nutriband CEO Gareth Sheridan published a letter to shareholders highlighting achievements and milestones in 2025, including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M, a 25% Preferred Stock dividend, and the expiration of warrants from the 2021 IPO on Oct 1, 2026. These moves aim to boost shareholder value and advance the commercialization of its lead product, AVERSA™ Fentanyl, a potential game-changer in the opioid transdermal patch market.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet